

IN THE CLAIMS:

1. (Original) A method of treating an immune-mediated disease in a patient comprising orally administering to said patient an immunoglobulin composition comprising Cohn Fraction II + III in an amount sufficient to provide a clinically observable improvement in the disease symptoms of said patient.
2. (Original) The method of Claim 1 wherein the amount of immunoglobulin composition which is administered to said patient is between 5 mg/kg to 5 g/kg per day.
3. (Original) The method of Claim 2 wherein the amount of immunoglobulin composition which is administered to said patient is about 1000 mg per day.
4. (Original) The method of Claim 1 wherein said immunoglobulin composition is administered in a unit dosage form.
5. (Original) The method of Claim 1 wherein said immunoglobulin composition is in a powdered form.
6. (Original) The method of Claim 1 wherein said immunoglobulin composition is dispersed in pharmaceutically acceptable carrier.
7. (Original) The method of Claim 1 wherein said immune-mediated disease is selected from the group consisting of rheumatoid arthritis, juvenile polyarticular rheumatoid arthritis, Still's disease, Sjogrens Syndrome, vasculitis, Systemic Lupus Erythematosus, peripheral

neuropathy, Raynauds Phenomenon, sensory-neural hearing loss (Meniere's Disease), fibromyalgia, inflammatory bowel disease (ulcerative colitis, Crohn's disease, and mucinous colitis), psoriatic arthritis, Reiter's Syndrome, ankylosing spondylitis, temporal arteritis, polymyalgia rheumatica and agammaglobulinemia.

8-9. (Cancelled)

10. (Original) A method of treating an immune-mediated disease in a patient comprising orally administering to said patient an immunoglobulin composition comprising Cohn Fraction II in an amount sufficient to provide a clinically observable improvement in the disease symptoms of said patient.

11. (Original) The method of Claim 10 wherein the amount of immunoglobulin composition which is administered to said patient is between 5 mg/kg to 5 g/kg per day.

12. (Original) The method of Claim 11 wherein the amount of immunoglobulin composition which is administered to said patient is about 1000 mg per day.

13. (Original) The method of Claim 10 wherein said immunoglobulin composition is administered in a unit dosage form.

14. (Original) The method of Claim 10 wherein said immunoglobulin composition is in a powdered form.

15. (Original) The method of Claim 10 wherein said immunoglobulin composition is dispersed in pharmaceutically acceptable carrier.

16. (Original) The method of Claim 10 wherein said immune-mediated disease is selected from the group consisting of rheumatoid arthritis, juvenile polyarticular rheumatoid arthritis, Still's disease, Sjogrens Syndrome, vasculitis, Systemic Lupus Erythematosus, peripheral neuropathy, Raynauds Phenomenon, sensory-neural hearing loss (Meniere's Disease), fibromyalgia, inflammatory bowel disease (ulcerative colitis, Crohn's disease, and mucinous colitis), psoriatic arthritis, Reiter's Syndrome, ankylosing spondylitis, temporal arteritis, polymyalgia rheumatica and agammaglobulinemia.

17-18. (Cancelled)

19. (Original) A method of treating an immune-mediated disease in a patient comprising orally administering to said patient an immunoglobulin composition comprising Cohn Fraction III in an amount sufficient to provide a clinically observable improvement in the disease symptoms of said patient.

20. (Original) The method of Claim 19 wherein the amount of immunoglobulin composition which is administered to said patient is between 5 mg/kg to 5 g/kg per day.

21. (Original) The method of Claim 20 wherein the amount of immunoglobulin composition which is administered to said patient is about 1000 mg per day.

22. (Original) The method of Claim 19 wherein said immunoglobulin composition is administered in a unit dosage form.

23. (Original) The method of Claim 19 wherein said immunoglobulin composition is in a powdered form.

24. (Original) The method of Claim 19 wherein said immunoglobulin composition is dispersed in pharmaceutically acceptable carrier.

25. (Original) The method of Claim 19 wherein said immune-mediated disease is selected from the group consisting of rheumatoid arthritis, juvenile polyarticular rheumatoid arthritis, Still's disease, Sjogrens Syndrome, vasculitis, Systemic Lupus Erythmatosus, peripheral neuropathy, Raynauds Phenomenon, sensory-neural hearing loss (Meniere's Disease), fibromyalgia, inflammatory bowel disease (ulcerative colitis, Crohn's disease, and mucinous colitis), psoriatic arthritis, Reiter's Syndrome, ankylosing spondylitis, temporal arteritis, polymyalgia rheumatica and agammaglobulinemia

26-28. (Cancelled)